Texas Pharmacy Shut Out of Controlled Substances by DEA
Published Date: 4/1/2025
Notice
Summary
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Baijes Bissonnet Pharmacy Registration Denied
Baijes Bissonnet Pharmacy's application for a DEA Certificate of Registration (Control No. W22147152A) is denied. The denial is effective May 1, 2025, and the Order also denies any other pending DEA registration application by Baijes Bissonnet Pharmacy in Texas.
Patients Lose Controlled-Med Access At Pharmacy
Customers who rely on Baijes Bissonnet Pharmacy in Stafford, Texas may no longer be able to obtain controlled-substance prescriptions there after May 1, 2025 because the pharmacy's DEA registration application was denied. The Order follows findings that the pharmacy repeatedly filled controlled-substance prescriptions with multiple red flags from at least March 2021 through August 2022.
Filling Red-Flag Prescriptions Risks Registration
The DEA found that repeatedly filling controlled-substance prescriptions that contained red flags (for example: pattern prescribing, cash payments, long-distance patients, and drug ‘cocktails’) supports denial of DEA registration. The Agency relied on factual findings including that 492 of 575 controlled-substance prescriptions (85%) were paid in cash and that 42 prescriptions to six individuals were essentially identical.
Missing Hearing Deadline Can Cause Default
The DEA deemed the applicant in default because it did not file a timely hearing request after being served the Order to Show Cause on December 19, 2023; the 30-day deadline for a hearing request ran to January 18, 2024. A default is deemed a waiver of the right to a hearing and an admission of the OSC allegations, which supported the Agency's request for final action.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05526 — Phong H. Tran, M.D.; Decision and Order
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Next: 2025-05528 — Mary Massullo, D.O.; Decision and Order
Mary Massullo, D.O., lost her license to handle controlled substances because she no longer has permission from Ohio, where she’s registered. She didn’t ask for a hearing, so the DEA decided to revoke her registration officially. This means she can’t legally work with controlled drugs anymore, and her registration expired on January 31, 2025.